Zuventus Healthcare Limited has issued a public clarification to reassure consumers, doctors, and business partners after false messages and rumours began circulating about the company’s alleged closure or rebranding.
The company categorically denied all such claims, stating that there has been no closure, suspension, or transfer of its business assets. Zuventus said its operations are running normally and its field staff continues to work at full strength across the country, ensuring uninterrupted availability of medicines and ongoing engagement with healthcare providers.
Addressing another point of confusion, Zuventus clarified that it has no association or affiliation with any entity named Zorvia Healthcare Limited. The company described these claims as inaccurate and misleading, and said they have caused unnecessary concern among consumers and other stakeholders.
Founded in 2002, Zuventus Healthcare is a subsidiary of Emcure Pharmaceuticals, which is listed on the Bombay Stock Exchange and the National Stock Exchange. The company reiterated its commitment to developing, manufacturing, and marketing high-quality and affordable medicines for patients across India.
Zuventus also said it is actively pursuing appropriate legal remedies to protect its goodwill and ensure that misleading information does not affect consumer trust. The company has a strong presence in branded generics, offering treatments for both chronic and acute conditions across cardiology, diabetology, gastroenterology, orthopaedics, pain management, and nutraceuticals.
Backed by robust manufacturing standards, a growing field force, and a patient-centric approach, Zuventus said its focus remains on improving health outcomes and maintaining long-term trust with patients and healthcare professionals. Consumers have been advised to rely only on official communications for accurate updates.
